Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Current Leases (2020 - 2026)

SAB Biotherapeutics filings provide 7 years of Current Leases readings, the most recent being $763705.0 for Q1 2026.

  • On a quarterly basis, Current Leases fell 3.74% to $763705.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $763705.0, a 3.74% decrease, with the full-year FY2025 number at $797402.0, up 459.33% from a year prior.
  • Current Leases hit $763705.0 in Q1 2026 for SAB Biotherapeutics, down from $797402.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.2 million in Q2 2022 to a low of $127022.0 in Q2 2023.
  • Median Current Leases over the past 5 years was $384892.0 (2024), compared with a mean of $433665.1.
  • Biggest five-year swings in Current Leases: plummeted 89.14% in 2023 and later surged 494.15% in 2025.
  • SAB Biotherapeutics' Current Leases stood at $490794.0 in 2022, then plummeted by 73.1% to $132004.0 in 2023, then grew by 8.0% to $142563.0 in 2024, then surged by 459.33% to $797402.0 in 2025, then decreased by 4.23% to $763705.0 in 2026.
  • The last three reported values for Current Leases were $763705.0 (Q1 2026), $797402.0 (Q4 2025), and $151033.0 (Q3 2025) per Business Quant data.